This is a preview of subscription content, log in via an institution to check access.
References
Levy-Lahad, E. Nat. Genet. 42, 368–369 (2010).
Meindl, A. et al. Nat. Genet. 42, 410–414 (2010).
Zheng, Y. et al. Breast Cancer Res. Treat. 124, 857–861 (2010).
Akbari, M.R. et al. Breast Cancer Res. 12, 404 (2010).
Silvestri, V. et al. Breast Cancer Res. 13, 404 (2011).
Wong, M.W. et al. Breast Cancer Res. Treat. 127, 853–859 (2011).
Romero, A. et al. Breast Cancer Res. Treat. 129, 939–946 (2011).
Pang, Z. et al. Breast Cancer Res. Treat. 129, 1019–1020 (2011).
Pelttari, L.M. et al. Hum. Mol. Genet. 20, 3278–3288 (2011).
Vuorela, M. et al. Breast Cancer Res. Treat. 130, 1003–1010 (2011).
Clague, J. et al. PLoS ONE 6, e25632 (2011).
Thompson, E.R. et al. Hum. Mutat. 33, 95–99 (2012).
Loveday, C. et al. Nat. Genet. 43, 879–882 (2011).
Ahmed, M. & Rahman, N. Oncogene 25, 5906–5911 (2006).
Seal, S. et al. Nat. Genet. 38, 1239–1241 (2006).
Acknowledgements
We thank all the subjects and families that participated in the research and the many individuals that assisted in their recruitment. We are grateful to R. Houlston for coordination of the collection of the unselected ovarian series. We acknowledge the use of DNA from the British 1958 Birth Cohort collection. We acknowledge NHS funding to the National Institute for Health Research (NIHR) Biomedical Research Centre. This work was funded by Cancer Research UK (C8620/A8372 and C8620/A8857) and the Institute of Cancer Research (UK). C.T. is a Medical Research Council (MRC)-funded Clinical Research Fellow. A.C.A. is a Cancer Research UK Senior Cancer Research Fellow (C12292/A11174). Informed consent was obtained from participants, and the research was approved by the London Multicentre Research Ethics Committee (MREC/01/2/18).
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Additional information
A full list of members is provided in the Supplementary Note.
Supplementary information
Supplementary Text and Figures
Supplementary Methods, Supplementary Figure 1, Supplementary Tables 1–3 and Supplementary Note (PDF 231 kb)
Rights and permissions
About this article
Cite this article
Loveday, C., Turnbull, C., Ruark, E. et al. Germline RAD51C mutations confer susceptibility to ovarian cancer. Nat Genet 44, 475–476 (2012). https://doi.org/10.1038/ng.2224
Published:
Issue Date:
DOI: https://doi.org/10.1038/ng.2224
- Springer Nature America, Inc.
This article is cited by
-
Germline variants associated with breast cancer in Khakass women of North Asia
Molecular Biology Reports (2023)
-
Activation of recombinational repair in Ewing sarcoma cells carrying EWS-FLI1 fusion gene by chromosome translocation
Scientific Reports (2022)
-
Integration of tumour sequencing and case–control data to assess pathogenicity of RAD51C missense variants in familial breast cancer
npj Breast Cancer (2022)
-
A recurrent pathogenic BRCA2 exon 5–11 duplication in the Christian Arab population in Israel
Familial Cancer (2022)
-
Cancer Predisposition Genes in Adolescents and Young Adults (AYAs): a Review Paper from the Italian AYA Working Group
Current Oncology Reports (2022)